Delaware court denies SIGA reargument in PharmAthene smallpox case
This article was originally published in Scrip
Executive Summary
Shares SIGA Technologies sunk as low as 8.6%, or 19 cents, on 19 December on word that the firm's motion for reargument was denied by a Delaware Chancery Court in a case in which the company was ordered in September to evenly split any profits it gains from the sale of its investigational smallpox antiviral drug ST-246 with PharmAthene (scripintelligence, 26 September 2011).